Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Amanda Clouser

Registered Nurse Springfield, IL Nurse Practitioner

NPI 1164087276 CMS profile 10520546

315 W Carpenter St Fl 1, Springfield, IL 62702

Open in the dashboard

General payments

$195

3 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Clouser of Springfield, IL is reported in the CMS Open Payments database as having received $195 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30 1
2024 General $165 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Clouser
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Amanda Clouser were reported at $30. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Amanda Clouser Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $53 $20–$148 $132
2022 $0 $53 $21–$146 $149
2023 $0 $84 $26–$196 $160
2024 $165 $80 $26–$187 $164
2025 $30 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Astellas Pharma US Inc $165 2 payments
  2. Vantive US Healthcare LLC $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Education $165 2 payments
  2. Food and Beverage $30 1 payment
Products named General payments · program years 2024–2025
  1. Renal - Acute $30 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

172

Median for Nurse Practitioner: 389

Drug cost

$22,146

Median for Nurse Practitioner: $21,885

Branded share of claims

44.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 19 $19,588
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 30 $838
Morphine Sulfate Er Morphine Sulfate Brand 17 $575
Anastrozole Generic 20 $445
Hydroxyurea Generic 12 $303
Letrozole Generic 16 $193
Ondansetron Hcl Generic 19 $83
Prochlorperazine Maleate Generic 13 $73
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $34
Allopurinol Generic 15 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$18,061

Medicare's payments for the services billed

Medicare patients

129

Average age 73

Services billed

242

73 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 60%
Arthritis 50%
Ischemic heart disease 45%
COPD 37%
Chronic kidney disease 32%
Diabetes 31%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record